• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Elanco (ELAN) Is Up 5.9% After Credelio Quattro Outperforms Rivals in Tick Protection Study

    Simply Wall St·08/01/2026 11:30:07
    语音播报
    • In July 2026, Elanco Animal Health reported new study results showing its Credelio Quattro chewable tablets kill black-legged and lone star ticks faster and more consistently through Day 28 than competing products Simparica Trio and NexGard Plus, while also carrying an FDA-approved claim for Lyme disease prevention in dogs.
    • An important angle for investors is that Credelio Quattro’s rapid tick kill and Lyme prevention claim differentiate it within a crowded pet parasiticide market, potentially strengthening Elanco’s broader innovation-focused portfolio.
    • We’ll now assess how Credelio Quattro’s faster, sustained tick kill profile could influence Elanco’s existing investment narrative around innovation-led growth.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Elanco Animal Health Investment Narrative Recap

    To own Elanco, you need to believe its innovation engine in pet and farm animal health can translate into profitable growth while it manages debt and spending. The new Credelio Quattro tick-speed data reinforces that innovation story and could support near term uptake, but the key near term catalyst remains execution on launches like Zenrelia and Credelio Quattro themselves. The biggest risk is that adoption and clinic penetration fall short of expectations, leaving margins and deleveraging under pressure.

    Among recent announcements, the 2025 “Leading with Purpose” Impact Report ties directly into this. It highlights Elanco’s intent to secure 5 to 6 potential blockbuster approvals by 2031, with Credelio Quattro clearly positioned as one of the early test cases. How well Credelio Quattro converts differentiated clinical data into real world demand will be an important proof point for that broader innovation focused story.

    Yet while Credelio Quattro’s profile looks promising, investors should also be aware that...

    Read the full narrative on Elanco Animal Health (it's free!)

    Elanco Animal Health's narrative projects $5.6 billion revenue and $247.5 million earnings by 2029. This requires 4.8% yearly revenue growth and a $489.5 million earnings increase from -$242.0 million today.

    Uncover how Elanco Animal Health's forecasts yield a $29.79 fair value, a 13% upside to its current price.

    Exploring Other Perspectives

    ELAN 1-Year Stock Price Chart
    ELAN 1-Year Stock Price Chart

    Some of the most optimistic analysts were already modeling revenue near US$5.8 billion and earnings around US$454 million by 2029, so this kind of data may strengthen their innovation driven view, but you should weigh that against the risk that elevated debt still constrains Elanco’s flexibility and consider how your own expectations compare to those more bullish forecasts.

    Explore 3 other fair value estimates on Elanco Animal Health - why the stock might be worth just $26.82!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Elanco Animal Health research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Elanco Animal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elanco Animal Health's overall financial health at a glance.

    Seeking Other Investments?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.